- A Phase II Study of Additional Four-Week Chemotherapy With Capecitabine During the Resting Periods After Six-Week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
-
Kyung Ha Lee, Min Sang Song, Jun Boem Park, Jin Soo Kim, Dae Young Kang, Ji Yeon Kim
-
Ann Coloproctol. 2013;29(5):192-197. Published online October 31, 2013
-
DOI: https://doi.org/10.3393/ac.2013.29.5.192
-
-
3,525
View
-
35
Download
-
5
Citations
-
 Abstract
 PDF
- Purpose
The aim of this study is to evaluate the efficacy and the safety of additional 4-week chemotherapy with capecitabine during the resting periods after a 6-week neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer. MethodsRadiotherapy was delivered to the whole pelvis at a total dose of 50.4 Gy for 6 weeks. Oral capecitabine was administered at a dose of 825 mg/m2 twice daily for 10 weeks. Surgery was performed 2-4 weeks following the completion of chemotherapy. ResultsBetween January 2010 and September 2011, 44 patients were enrolled. Forty-three patients underwent surgery, and 41 patients completed the scheduled treatment. Pathologic complete remission (pCR) was noted in 9 patients (20.9%). T down-staging and N down-staging were observed in 32 patients (74.4%) and 33 patients (76.7%), respectively. Grade 3 to 5 toxicity was noted in 5 patients (11.4%). The pCR rate was similar with the pCR rates obtained after conventional NCRT at our institute and at other institutes. ConclusionThis study showed that additional 4-week chemotherapy with capecitabine during the resting periods after 6-week NCRT was safe, but it was no more effective than conventional NCRT.
-
Citations
Citations to this article as recorded by  - Locally Advanced Rectal Cancer: What We Learned in the Last Two Decades and the Future Perspectives
Vivek Srivastava, Aakansha Giri Goswami, Somprakas Basu, Vijay Kumar Shukla
Journal of Gastrointestinal Cancer.2023; 54(1): 188. CrossRef - The Effect of Continuing Chemotherapy after Chemoradiotherapy during the Time to Surgery on Tumor Response and Survival for Local Advanced Rectal Cancer
Atike Gökçen Demiray, Arzu Yaren, Uğur Sungurtekin, Papatya Bahar Baltalarlı, Neşe Demirkan, Duygu Herek, Burcu Yapar Taşköylü, Gamze Gököz Doğu, Serkan Değirmencioğlu, Utku Özgen, Halil Sağınç, Umut Çakıroğlu, Nail Özhan, Canan Karan, Burçin Çakan Demire
Journal of Oncology.2022; 2022: 1. CrossRef - Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review
Mark T.W. Teo, Lucy McParland, Ane L. Appelt, David Sebag-Montefiore
International Journal of Radiation Oncology*Biology*Physics.2018; 100(1): 146. CrossRef - Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial
Shapour Omidvari, Shadi Zohourinia, Mansour Ansari, Leila Ghahramani, Mohammad Zare-Bandamiri, Ahmad Mosalaei, Niloofar Ahmadloo, Saeedeh Pourahmad, Hamid Nasrolahi, Sayed Hasan Hamedi, Mohammad Mohammadianpanah
Annals of Coloproctology.2015; 31(4): 123. CrossRef - Additional Chemotherapy During Resting Periods After Preoperative Chemoradiotherapy in Patients With Rectal Cancer
Ok Suk Bae
Annals of Coloproctology.2013; 29(5): 178. CrossRef
|
KSCP
APFCP
SIUCP-ETS
